Table 3 Major clinical trials comprising epidrugs and immunotherapy for cancer treatment
From: Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
Clinical trial | Phase | State | Cancer | Combination | Dates |
|---|---|---|---|---|---|
NCT01928576 | II | Recruiting | Non-small cell lung cancer | Nivolumab Entinostat Azacitidine | 2013-estimated end 2022 |
NCT02260440 | II | Completed | Metastatic colorectal cancer | Pembrolizumab Azacitidine | 2015–2017 |
NCT02546986 | II | Active, not recruiting | Non-small cell lung carcinoma | CC-486 Pembrolizumab | 2015-estimated end 2021 |
NCT02453620 | I | Active, not recruiting | Breast Cancer | Ipilimumab Nivolumab Entinostat | 2015-estimated end 2021 |
NCT02961101 | I/II | Recruiting | Non-Hodgkin lymphoma, Hodgkin lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer, lung cancer, renal-cell cancer, pancreatic cancer and bile duct cancer | Anti-PD-1 antibody Decitabine Chemotherapy | 2016–2020 |
NCT02890069 | I | Recruiting | Colorectal cancer Non-small cell lung adenocarcinoma Triple-negative breast cancer Renal cell carcinoma | PDR001 (Anti-PD-1 antibody) Everolimus Panobinostat | 2016-estimated end 2021 |
NCT02619253 | I/Ib | Active, not recruiting | Renal cell carcinoma Urinary bladder neoplasms | Pembrolizumab Vorinostat | 2016-estimated end 2022 |
NCT02512172 | I | Active, not recruiting | Colorectal cancer | CC-486 (Oral 5-Aza) Romidepsin MK–3475 (Anti-PD-1 antibody) | 2016-estimated end 2022 |
NCT02811497 | II | Active, not recruiting | Microsatellite stable colorectal carcinoma Platinum-resistant epithelial ovarian cancer type II Estrogen receptor-positive and HER2-negative breast cancer | Durvalumab Azacitidine | 2016-estimated end 2022 |
NCT02957968 | II | Recruiting | Breast cancer | Decitabine Pembrolizumab Doxorubicin Cyclophosphamide Paclitaxel Carboplatin | 2016-estimated end 2023 |
NCT02638090 | I/II | Recruiting | Lung cancer | Vorinostat Pembrolizumab | 2016-estimated end 2023 |
NCT02959437 | I/II | Completed | Advanced or metastatic solid tumors | Azacitidine Pembrolizumab Epacadostat INCB057643 (BET inhibitor) INCB059872 (LSD1 inhibitor) | 2017–2020 |
NCT03308396 | Ib/II | Active, not recruiting | Advanced kidney cancer Kidney cancer Clear cell renal cell carcinoma | Durvalumab Guadecitabine | 2017-estimated end 2021 |
NCT03206047 | I/II | Active, not recruiting | Platinum-resistant fallopian tube carcinoma Platinum-resistant ovarian carcinoma Platinum-resistant primary peritoneal carcinoma Recurrent fallopian tube carcinoma Recurrent ovarian carcinoma Recurrent primary peritoneal carcinoma | Atezolizumab Guadecitabine | 2017-estimated end 2021 |
NCT03264404 | II | Recruiting | Pancreas cancer | Pembrolizumab Azacitidine | 2017-estimated end 2021 |
NCT03179943 | II | Active, not recruiting | Urothelial carcinoma | Atezolizumab Guadecitabine | 2017-estimated end 2022 |
NCT03019003 | I/II | Recruiting | Head and neck cancer | Durvalumab Oral Decitabine | 2017-estimated end 2024 |
NCT02816021 | II | Recruiting | Melanoma and other malignant neoplasms of skin Metastatic melanoma | Pembrolizumab Azacitidine | 2017-estimated end 2026 |
NCT03590054 | I | Recruiting | Melanoma Metastatic head and neck squamous cell carcinoma Urothelial carcinoma Non-small cell lung carcinoma | Pembrolizumab Abexinostat | 2018-estimated end 2022 |
NCT03426891 | I | Recruiting | Glioblastoma Brain tumor | Pembrolizumab Vorinostat Temozolomide | 2018-estimated end 2022 |
NCT03233724 | I/II | Recruiting | Non-small cell lung Cancer Esophageal carcinoma Malignant pleural mesotheliomas | Pembrolizumab Decitabine Tetrahydrouridine (THU) | 2018-estimated end 2026 |
NCT03854474 | I/II | Recruiting | Locally and metastatic urothelial carcinoma | Pembrolizumab Tazemetostat | 2019-estimated end 2021 |
NCT03812796 | II | Recruiting | Gastrointestinal cancer | Domatinostat Avelumab | 2019-estimated end 2021 |
NCT03765229 | II | Recruiting | Melanoma | Pembrolizumab Entinostat | 2019-estimated end 2023 |
NCT03978624 | II | Recruiting | Bladder cancer | Pembrolizumab Entinostat | 2020-estimated end 2022 |
NCT04357873 | II | Recruiting | Squamous cell lung cancer Vulvar cancer Penile cancer Cervix cancer Head and neck squamous cell carcinoma Anal cancer | Pembrolizumab Vorinostat | 2020-estimated end 2024 |
NCT04624113 | I/II | Not yet recruiting | Head and neck squamous cell carcinoma | Pembrolizumab Tazemetostat | 2021-estimated end 2024 |
NCT04190056 | II | Not yet recruiting | Breast cancer | Pembrolizumab Tamoxifen Vorinostat | 2021-estimated end 2029 |